Market Outlook

Celgene’s Revlimid and Janssen/Takeda Pharmaceutical’s Velcade are the cornerstones of therapy for multiple myeloma. Successive label expansions have driven significant commercial reward for some well-entrenched current therapies. Emerging agents such as AbbVie/Roche/Genentech’s Venclexta/Venclyxto, Karyopharm Therapeutics’ selinexor, Sanofi/ImmunoGen’s isatuximab, and Bluebird Bio/Celgene’s bb2121 are pursuing initial approvals for the treatment of multiple myeloma, highlighting that untapped clinical and commercial potential exists in multiple myeloma for therapies with improved efficacy, novel mechanisms of action, and positioned in patient segments that are currently underserved.

Questions Answered

  • Revlimid and Velcade are widely used for the current treatment of multiple myeloma, but how will the use of these agents change over the forecast period? What impact will generic entries of these pivotal agents have on the multiple myeloma market?
  • How has the approval of Janssen’s Darzalex and Bristol-Myers Squibb/AbbVie’s Empliciti impacted the multiple myeloma market? How important will these agents become over the forecast period?
  • What are thought-leaders’ opinions on agents in Phase III development, such as Merck & Co.’s Keytruda, Bristol-Myers Squibb/Ono Pharmaceutical’s Opdivo, Sanofi/ImmunoGen’s isatuximab, Bluebird Bio/Celgene’s bb2121, and GlaxoSmithKline’s GSK2857916? What impact will these agents have on the multiple myeloma market?
  • What are the drivers and constraints in the multiple myeloma market, and how will the market evolve over the forecast period?

Product Description

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Idiopathic Pulmonary Fibrosis - Epidemiology - Mature Markets

Author(s): Devashri Mukherjee, MPH; Alison Isherwood, MSc, MRes, PhD

Research enthusiast with a flair for academic writing, member of the DRG family since April 2015 and working from the India office.

Started off career with a bachelor’s in Dental Surgery followed by a master’s in Public health; having primarily worked in the hospital setting as a Research Consultant prior to DRG and with 10 international publications to my credit.

Alison Isherwood, B.Sc., M.Res., M.Sc., Ph.D. joined Decision Resources Group in 2008, as an Epidemiologist. Alison holds a B.Sc. in Medical Microbiology, Masters by Research in the Life Sciences and a M.Sc. in Epidemiology all from the University of Edinburgh. Prior to joining Decision Resources Inc., she was working on her Ph.D. in Molecular Virology, specializing on the severe acute respiratory syndrome (SARS) coronavirus, at the University of Reading. In her role at Decision Resources Group, Alison is currently an Epidemiology team lead as well as project managing custom epidemiology work in multiple therapy areas. Alison’s area of specialization at DRG is cancer, particularly breast cancer.


Related Reports

Multiple Myeloma - Landscape & Forecast - Disease Landscape & Forecast

Market Outlook The availability of premium-priced branded agents prescribed in doublet, triplet, and quadruplet regimens, particularly Darzalex-based therapies, has had an...

View Details

Idiopathic Pulmonary Fibrosis - Epidemiology - Extrapolated Worldwide Coverage

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key idiopathic pulmonary fib...

View Details

Idiopathic Pulmonary Fibrosis - Landscape & Forecast - Disease Landscape & Forecast

Idiopathic pulmonary fibrosis (IPF) is one of the most common interstitial lung diseases and is characterized by an ir...

View Details

Idiopathic Pulmonary Fibrosis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. It is characterized by an irr...

View Details